logo

Indian News

Share

Pharma-011818.jpg Today's Daily Dose brings you news about Aeterna's alliance with Strongbridge; a new study about CellMax-CRC Colorectal Cancer Screening test and Novartis' Kymriah getting priority review from the FDA for a second indication.

Jan17-up-011718.jpg The following are some of today's top gainers in the pharma/biotech sector.

Pharma-011718.jpg Today's Daily Dose brings you news about Juno's suitor; Eiger's failed LIBERTY trial; encouraging hepatocellular carcinoma trial data of Ipsen and Exelixis; MiMedx's progress in recalcitrant plantar fasciitis pain trial; positive FDA feedback related to the design of Athenex's breast cancer trial and MabVax's clinical trial catalysts to watch out for this quarter.

Pharma-011518.jpg The following are some of today's top gainers in the pharma/biotech sector.

spectrumofNAFLD-011618.jpg Although there are a number of investigational NASH therapies in various stages of development, there is no approved drug yet for this silent killer. However, the fact that the race to develop an effective drug against NASH has reached the home stretch is welcome news for patients. The very earliest NASH drug could hit the market is 2021, assuming all goes well as planned.

Follow RTT